Excessive Sweating Caused by Antidepressants: Measurement and Treatment With Terazosin

Condition(s) targeted: Hyperhidrosis

Intervention: terazosin (Drug)

Phase: Phase 4

Status: Recruiting

Sponsored by: Thomas Jefferson University

Official(s) and/or principal investigator(s):
Rajnish Mago, MD, Principal Investigator, Affiliation: Thomas Jefferson University

Overall contact:
Shannon Duffany, BA, Phone: 215-503-1662, Email: shannon.duffany@jefferson.edu

The study consists of measurement of antidepressant-induced excessive sweating and its treatment with an experimental medication, terazosin (approved for hypertension), that will be added to the antidepressant. This study is for people who take an antidressant due to a depressive disorder. This is an open-label study (no placebo group) that will last 5 weeks, with one week of baseline measurement and four weeks of treatment with the study medication. The study is based on the hypothesis that terazosin will be effective in reducing the severity of excessive sweating caused by antidepressant treatment, and will have minimal side-effects.

Official title: Antidepressant Induced Excessive Sweating: Measurement and Treatment With Terazosin

Study design: Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Primary outcome:

To study whether terazosin 1 to 4 mg/ day is effective in reducing antidepressant-induced sweating

To test a novel device for ambulatory monitoring of sweating which is required to study this phenomenon since ADIES is usually episodic

Secondary outcome:

To determine if the severity of sweating at baseline is correlated with baseline urinary norepinephrine levels

To determine if response to treatment correlated with baseline urinary norepinephrine levels and with changes in these levels during the study.

Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

1. Age 18 - 75 years

2. Clinical diagnosis of a Depressive disorder (Diagnostic and Statistical Manual of Mental Disorders – IV-TR)

3. Presence of excessive sweating by self-report

4. The excessive sweating started after initiation of an antidepressant and, if treatment with the antidepressant was interrupted, did not persist for more than 4 weeks during that interruption

5. Treatment with the antidepressant is deemed to be clinically necessary due to substantial benefit from this antidepressant, and failure to respond to or tolerate an alternative

6. Excessive sweating has persisted for at least 4 weeks prior to baseline assessment

7. The excessive sweating is rated by the patient as at least moderately bothersome.

8. Episodes of excessive sweating occur at least twice a week for last 4 weeks

Exclusion Criteria:

1. Presence of another known disease that could potentially cause excessive sweating

2. Failure to respond to antiadrenergic (reducing activity of the sympathetic nervous system) treatment in the past

3. Blood pressure less than 110 mm Hg systolic at the screening or baseline visits

4. Orthostatic hypotension by history or on assessment at the screening or baseline visits (defined as a decrease of 10 mm Hg or greater after standing for 2 minutes).

5. Current antihypertensive treatment

6. History of significant cardiac disease, including coronary artery disease

7. Current use of phosphodiesterase type 5 inhibitors: sildenafil (ViagraTM), tadalafil (CialisTM), or vardenafil (LevitraTM)

8. History of priapism (persistent and painful erection)

Shannon Duffany, BA, Phone: 215-503-1662, Email: shannon.duffany@jefferson.edu

Thomas Jefferson University, Department of Psychiatry, Philadelphia, Pennsylvania 19107, United States; Recruiting
Shannon Duffany, BA, Phone: 215-503-1662, Email: shannon.duffany@jefferson.edu
Rajnish Mago, MD, Principal Investigator

Starting date: March 2007
Last updated: March 19, 2007